Olanzapine

Generic Name: Olanzapine

Brand Names: Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀N_₄S

CAS Number: 132539-06-1

Unique Ingredient Identifier: N7U69T4SZR

Background: Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...

Indication: Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...

Associated Conditions: Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Associated Therapies: -

Clinical Trials

Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine

Phase 3

Completed

Conditions: Bipolar Disorder I or II

Interventions: Drug: olanzapine

First Posted Date: 2005-11-29

Last Posted Date: 2009-06-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 141

Registration Number: NCT00259272

Locations: 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

Phase 1

Completed

Conditions: Dyskinesia, Drug-Induced

First Posted Date: 2005-11-21

Last Posted Date: 2013-06-06

Lead Sponsor: University of California, San Diego

Target Recruit Count: 250

Registration Number: NCT00255879

Locations: 🇺🇸
University of California, San Diego Division of Geriatric Psychiatry, San Diego, California, United States

Side Effects of Newer Antipsychotics in Older Adults

Phase 4

Completed

Conditions: Schizophrenia
Alzheimer's Disease
Dementia

Interventions: Drug: Risperidone
Drug: Aripiprazole
Drug: Olanzapine

First Posted Date: 2005-10-27

Last Posted Date: 2018-12-17

Lead Sponsor: Veterans Medical Research Foundation

Target Recruit Count: 406

Registration Number: NCT00245206

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States

Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2005-10-14

Last Posted Date: 2021-02-21

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 112

Registration Number: NCT00239109

Locations: 🇪🇸
Pfizer Investigational Site, Zamora, Spain

A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder

Phase 4

Completed

Conditions: Schizophrenia
Diabetes Mellitus

Interventions: Drug: Risperidone
Drug: Olanzapine

First Posted Date: 2005-10-12

Last Posted Date: 2011-05-17

Lead Sponsor: Janssen, LP

Target Recruit Count: 59

Registration Number: NCT00236379

Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2005-10-12

Last Posted Date: 2014-06-06

Lead Sponsor: Yale University

Registration Number: NCT00237861

A Comparative Study of New Medications for Psychosis in Adolescents

Not Applicable

Completed

Conditions: Psychotic Disorders
Schizophrenia
Schizophreniform Disorders
Schizoaffective Disorders

First Posted Date: 2005-09-22

Last Posted Date: 2006-09-11

Lead Sponsor: University of Minnesota

Target Recruit Count: 30

Registration Number: NCT00222495

Locations: 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)

Phase 3

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: asenapine
Drug: olanzapine

First Posted Date: 2005-09-21

Last Posted Date: 2022-02-16

Lead Sponsor: Organon and Co

Target Recruit Count: 440

Registration Number: NCT00212771

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)

Phase 3

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: asenapine
Drug: olanzapine

First Posted Date: 2005-09-21

Last Posted Date: 2024-08-15

Lead Sponsor: Organon and Co

Target Recruit Count: 1225

Registration Number: NCT00212784

A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

Phase 4

Completed

Conditions: Senile Dementia, Alzheimer Type
Dementia
Dementia, Alzheimer Type
Alzheimer Disease

First Posted Date: 2005-09-21

Last Posted Date: 2013-11-13

Lead Sponsor: Emory University

Target Recruit Count: 50

Registration Number: NCT00208819

Locations: 🇺🇸
Wesley Woods Geriatric Hospital, Atlanta, Georgia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy